Overview of Cataflam QS

Property	Description
Active ingredient	Diclofenac potassium
Form	Film-coated tablets, Immediate-release (QS)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Pain, Inflammation, and Fever Reduction
Origin	Synthetic compound (Phenylacetic acid derivative)

What Type of Medicine is Cataflam QS?

Cataflam QS is a prescription-only brand-name medication whose active ingredient, diclofenac potassium, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The drug is a synthetic compound that provides general relief by targeting the body's processes of pain and inflammation at their biological source. This classification is clinically recognized. Diclofenac is one of the most widely used NSAIDs globally.

Composition and the Quick Start (QS) Formulation

The key component in Cataflam QS is diclofenac potassium, a single-ingredient compound presented as a film-coated tablet for oral administration. The distinctive “QS” (Quick Start) designation refers to this specialized formulation, which utilizes the potassium salt of diclofenac to facilitate immediate-release characteristics. This design allows the medication to dissolve and be absorbed into the bloodstream more rapidly than standard diclofenac base or conventional tablet forms.

The General Purpose and Benefit of Diclofenac Potassium

The primary general purpose of Cataflam QS is to provide rapid symptomatic relief by interrupting the inflammatory cascade in the body. By suppressing the production of prostaglandins—the chemical messengers that trigger pain and swelling—the medication acts simultaneously as an analgesic (pain reducer), an anti-inflammatory agent (swelling reducer), and an antipyretic (fever reducer). This rapid action capability is the core benefit, enabling the quick management of acute inflammatory pain.

What side effects are possible with Cataflam QS?

Cataflam QS: Possible Side Effects and Safety Information

Cataflam QS (diclofenac potassium) carries an increased risk of serious, potentially fatal cardiovascular (CV) thrombotic events (including myocardial infarction and stroke) and serious gastrointestinal (GI) adverse events (including bleeding, ulceration, and perforation of the stomach or intestines). These serious events can occur without warning and the CV risk may increase with the duration and higher dosage of use. To minimize these risks, regulatory documents emphasize using the lowest effective dose for the shortest duration necessary.

Serious and Clinically Significant Adverse Reactions

Cardiovascular: Fatal thrombotic events, new onset or worsening hypertension (blood pressure must be monitored closely), and congestive heart failure.
Gastrointestinal: Serious GI bleeding, ulceration, and perforation, which may be fatal. Elderly patients are at greater risk.
Hepatic (Liver): Severe liver reactions, including liver necrosis and fatal fulminant hepatitis, have been reported. Liver function should be monitored.
Renal (Kidney): Risk of renal toxicity, including acute renal failure and papillary necrosis. Use with caution in patients with fluid retention or heart failure.
Hypersensitivity: Severe, sometimes fatal, anaphylactic reactions and life-threatening skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Common Side Effects

Commonly reported side effects often involve the gastrointestinal system and may include abdominal pain, nausea, vomiting, diarrhea, constipation, dyspepsia, gas, and headache or dizziness.

Safety Restrictions and Contraindications

Cataflam QS is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It must not be used by patients with a history of allergic reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs. Use during the third trimester of pregnancy is also contraindicated due to the risk of premature closure of the fetal ductus arteriosus.

Overdose and Emergency Response

Overdose and when to seek help

Overdose manifestations with diclofenac potassium, consistent with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), involve documented effects on the gastrointestinal and central nervous systems. Clinical presentations of a massive oral overdose may include nausea, vomiting, epigastric pain, and signs of gastrointestinal bleeding. Central nervous system signs such as lethargy, drowsiness, dizziness, and tinnitus have also been officially recorded.

The regulatory profile highlights that severe or life-threatening outcomes can occur in acute massive ingestions. These officially documented complications include acute renal failure (which may present as little or no urine output), seizures, coma, and hypotension. Patients with pre-existing renal impairment may be noted as having an increased risk for these severe renal outcomes.

Required Emergency Action

As mandated by regulatory authorities, immediate medical attention must be sought in all cases of suspected overdose. Given that no specific antidote exists for diclofenac poisoning, all management is symptomatic and supportive. Emergency services must be contacted immediately if severe signs are present, such as loss of consciousness, severe gastrointestinal bleeding, or seizures. Officially described procedures include continuous monitoring of vital signs and consideration of gastric decontamination measures, such as activated charcoal, if deemed appropriate.

Therapeutic Uses of Cataflam QS

What Cataflam QS Treats: Main Uses and Benefits

Cataflam QS (diclofenac potassium immediate-release) is a prescription medication that is commonly used to provide symptomatic relief across several conditions presenting with systemic or localized discomfort. Its primary benefit is providing support that helps ease the overall symptom burden, assisting patients in coping more steadily with difficult and acute symptom episodes.

Key Areas of Symptom Management

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and plays a role in managing symptoms related to inflammatory or irritative states. It is commonly used to help with managing pain and swelling associated with flare-ups of chronic conditions like osteoarthritis and rheumatoid arthritis; acute injuries such as sprains and strains; post-operative discomfort following dental surgery; and episodic pain events like primary dysmenorrhea (menstrual cramps) and migraine attacks.

“This medication is commonly used when short-term symptomatic assistance is needed and helps address symptom clusters that may become intense or disruptive.”

This use is relevant when supportive symptom management is appropriate and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Discomfort Cataflam QS is particularly relevant for easing symptoms that interfere with daily comfort when associated with sudden inflammation, post-injury swelling, or the onset of menstrual or migraine pain.

Eligibility and Restrictions for Use

Cataflam QS (diclofenac potassium) eligibility is strictly defined by regulatory documents, distinguishing between populations that are permitted, restricted, or absolutely prohibited from use.

Populations for Whom Use is Contraindicated

Absolute contraindications mean the medicine must not be used. These include patients with known hypersensitivity to diclofenac or a history of allergic-type reactions to aspirin or other NSAIDs (e.g., asthma, urticaria). Use is prohibited in patients with active gastrointestinal ulceration, bleeding, or perforation, severe hepatic or renal failure, and severe heart failure (NYHA Class II–IV). The medicine is also contraindicated for treating pain related to coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy.

Eligibility Restrictions and Special Use

Category	Regulatory Status
Pediatric Patients	Not approved for use in those under 18 years (US FDA). Not recommended under 14 years in some regions.
Pregnancy	Contraindicated in the third trimester. Use should be limited between 20 and 30 weeks.
Organ Impairment	Contraindicated in severe hepatic/renal failure. Caution is required for mild-to-moderate impairment.
Elderly Patients	Caution is indicated; use the lowest effective dose for the shortest duration.

The regulatory profile defines eligibility primarily by organ function integrity and prior clinical history to manage specific risks. Patients with cardiovascular risk factors, uncontrolled hypertension, or a history of GI disease require conditional use with close medical surveillance.

What should I know about interactions with other medicines?

Cataflam QS (diclofenac potassium) is a nonsteroidal anti-inflammatory drug (NSAID) and can interact with numerous other medications, potentially increasing the risk of adverse effects, such as gastrointestinal bleeding or kidney dysfunction. It is crucial to inform your healthcare provider of all prescription, over-the-counter, and herbal products you are currently taking.

Major Interaction Categories

Concomitant Medicine Category	Potential Interaction Result
Other NSAIDs or Aspirin	Increased risk of serious gastrointestinal bleeding, ulceration, and kidney problems. The combination is generally not recommended.
Anticoagulants/Blood Thinners (e.g., warfarin, apixaban)	Significantly increased risk of bleeding and hemorrhage. Close monitoring is essential.
Antiplatelet Agents (e.g., clopidogrel)	Increased risk of serious bleeding.

Other Important Interactions

Diclofenac may reduce the effectiveness of certain blood pressure medications (antihypertensives), including ACE inhibitors (e.g., lisinopril) and Angiotensin II Receptor Blockers (ARBs, e.g., losartan), and diuretics (water pills, e.g., furosemide), while also increasing the risk of kidney problems when combined with these.

Concomitant use with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (types of antidepressants) can increase the risk of gastrointestinal bleeding. Drugs like lithium and methotrexate may have their plasma concentrations increased when taken with Cataflam QS, leading to a higher risk of toxicity.

Alcohol consumption should be limited or avoided as it further increases the risk of stomach bleeding associated with all NSAIDs. Consult your doctor for personalized guidance before combining any medication with Cataflam QS.

Mechanism of Action

Mechanism of Action (Pharmacodynamics)

Cataflam QS (diclofenac) operates through the non-selective inhibition of Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This binding interaction blocks the conversion of arachidonic acid into prostanoids, including prostaglandins and thromboxanes, within the arachidonic acid cascade.

This reduction in prostanoid synthesis modifies early molecular steps that shape systemic physiological outcomes. Specifically, it inhibits the sensitization of peripheral nociceptors and attenuates local inflammatory responses characterized by vasodilation and edema. This mechanism contributes to the modulation of prostanoid-driven physiological signaling.

Due to the non-selective action on COX-1, the mechanism also involves transient alteration of platelet aggregation (mediated by thromboxane A2) and a reduction in prostaglandins that contribute to gastric mucosal defense, reflecting modulation of core homeostatic systems.

Dosage and Administration Information

How to Use Cataflam QS

This section outlines the instructions for the proper administration and dosing of Cataflam QS (diclofenac potassium immediate-release 50 mg tablets).

Administration Scope


Route of administration	The medicine is for oral administration.
Dosing schedule	The typical daily dose ranges from 100 mg to 150 mg, administered in divided doses. A maximum daily dose of 150 mg should generally not be exceeded, though a total of 200 mg per day may be used for acute episodes like migraine.
Timing in relation to meals	The tablet is preferably taken before meals to align with the formulation's rapid absorption characteristics.
Preparation requirements	The tablets must be swallowed whole with liquid and must not be divided, crushed, or chewed.
Age-group administration rules	The tablet is generally not recommended for children under 14 years of age. For older adults, no initial dose adjustment is required, but the lowest effective dose should be used.
Special procedural conditions	The overarching principle is to utilize the lowest effective dose for the shortest duration necessary to manage symptoms. The immediate-release formulation is not necessarily interchangeable with other diclofenac forms, such as extended-release tablets.

Instruction Classifications


Administration method type	Oral.
Frequency pattern	Divided daily use (two or three times daily) or as-needed (e.g., for acute migraine attacks, with doses taken at 4-to-6-hour intervals if needed).
Instructional basis	Governed by official prescribing information and equivalent national documents.

Resulting Procedural Structure

The official instruction sequence establishes a clear, divided-dose oral protocol:

The 50 mg tablet is taken orally and swallowed whole, preferably before meals.
The dose is maintained within the official daily limits and administered according to the required divided-dose frequency.
The use of the drug is defined as short-term, adhering to the principle of using the lowest dose for the shortest possible duration.

Recent Clinical Evidence

Research evidence / Overview of studies for Cataflam QS

Evidence for Acute Pain Relief and Primary Dysmenorrhea

Research has explored the use of this immediate-release formulation for conditions characterized by fluctuating or episodic manifestations, specifically acute general pain and primary dysmenorrhea (menstrual cramps). The studies were predominantly designed as Randomized Controlled Trials (RCTs), where researchers examined short-term symptom changes. In these research settings, studies documented patterns related to symptom evolution in the observed populations. Findings describe patterns related to systemic absorption, which was studied for this specific formulation. The research studies highlights changes measured during the study period, focusing primarily on the first few hours following a single administration.

However, the existing evidence is limited largely to short-term observation in generally healthy adult populations. The scope of these initial studies means that the long-term effects are not fully established, and there is limited information on outcomes over repeated use across multiple symptom cycles.

Research on Symptoms of Osteoarthritis and Rheumatoid Arthritis

This formulation was studied for use in conditions marked by functional limitations, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). The evidence base for this application includes specific controlled clinical trials and is contextualized by information derived from the broader diclofenac drug class. Studies examined outcomes related to the signs and symptoms associated with the conditions, including patient-reported outcomes describing perceived discomfort. The primary reported focus of the immediate-release formulation was on achieving quick systemic drug concentration during periods of heightened symptom activity.

A key research limitation is that dedicated, long-duration evidence for this specific immediate-release preparation is limited. Much of the understanding regarding its use for chronic symptom management relies on extrapolation from evidence established for other, non-immediate-release formulations of diclofenac.

Unanswered Questions and Research Gaps

Research highlights what is known and what is still uncertain about this formulation. The primary limitation is the focus on short-term symptom changes and acute episodes. Follow-up durations were limited, and for some specific trials, the sample sizes were modest. Certainty remains low for findings in certain patient groups, and data for certain groups remain insufficient when considering older adults or patients with complex health issues. The available research studies help show what has been observed so far but does not provide individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Cataflam QS (FAQ)

Q: What kind of pain is Cataflam QS specifically approved to treat?

According to the official product information, Cataflam QS (diclofenac potassium) is indicated for the short-term relief of mild to moderate acute pain. It is also approved specifically for the treatment of primary dysmenorrhea (menstrual cramps).

Q: Is Cataflam QS classified as a narcotic or opioid?

No, Cataflam QS is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not a narcotic or an opioid, nor is it classified as a controlled substance.

Q: Are there different strengths or dosages of Cataflam QS available for prescribing?

The immediate-release tablet form of Cataflam (diclofenac potassium) is primarily available in a 50 mg strength. The medicine’s official regulatory profile defines dosing based on the condition being treated.

Q: Is the active ingredient in Cataflam QS available in generic form?

Yes, the active ingredient in Cataflam QS, diclofenac potassium, is widely available in generic form, as confirmed by regulatory bodies like the FDA.

Q: What is the clinical difference between potassium and sodium forms of diclofenac?

The key clinical difference is the formulation for absorption. The potassium salt (in Cataflam QS) is designed for immediate release and faster absorption, making it suitable for acute pain conditions. The sodium salt is often formulated for delayed or extended release.

Q: What is the difference between Cataflam QS and regular Cataflam?

Cataflam QS contains diclofenac potassium, an immediate-release formulation. This salt form allows for rapid absorption compared to other salt forms of the medicine, which is a feature highlighted in official product documentation.

Q: Are there any known long-term side effects associated with prolonged use of Cataflam QS?

Official regulatory warnings state that the risks of serious cardiovascular (CV) thrombotic events and serious gastrointestinal (GI) adverse events may increase with the duration of use. The official principle is to utilize the lowest effective dose for the shortest duration necessary to manage symptoms.

Q: Is drowsiness a reported side effect of Cataflam QS?

Yes, regulatory documents list drowsiness as a possible side effect, though it is described as less common than other reported effects. The official labeling describes this as a possible event.

Q: What are the official warning signs for an allergic reaction to Cataflam QS?

Official warning signs for a serious reaction include difficulty breathing or wheezing, swelling of the face, lips, tongue, or throat, hives, itching, or skin rash. These events require prompt medical intervention as described in the drug's safety information.

Q: Can Cataflam QS be taken safely with blood thinners?

Taking this medicine with anticoagulants (blood thinners) is associated with an increased risk of bleeding and hemorrhage. Official product information indicates that close medical supervision and frequent monitoring are essential when these drugs are used together.

Q: How quickly can a person typically expect Cataflam QS to start relieving pain?

The immediate-release formulation (QS) is specifically designed for rapid absorption. This allows the drug to quickly reach effective concentrations in the bloodstream to achieve faster pain relief compared to delayed-release formulations.

Q: When is the maximum pain relief effect of Cataflam QS usually reached?

Due to its immediate-release design, the medicine is intended to achieve its peak drug concentration in the bloodstream quickly, generally within the first two hours after administration.

Q: Does taking Cataflam QS with food typically alter its speed of action?

The medicine is preferably taken before meals to promote its rapid absorption. Regulatory documents indicate that taking it with food may slightly reduce the speed of action or the overall effectiveness.

Q: Can individuals with a history of kidney issues safely use Cataflam QS?

Use of this medicine is contraindicated in cases of severe kidney failure (advanced renal disease). The drug's profile indicates that caution is necessary and monitoring of kidney function is advised in the presence of mild-to-moderate kidney impairment.

Q: Is Cataflam QS safe for patients who have previously had stomach ulcers?

The official label notes that caution is needed for patients with a prior history of ulcer disease or GI bleeding. The drug is contraindicated in patients with active ulceration, but the focus for history is the necessary caution due to the risk of recurrence.

Q: Is it safe for a nursing mother to use Cataflam QS?

Official labeling addresses the balance of discontinuing nursing or discontinuing the medicine. This consideration is based on the importance of the medicine to the mother and the potential for serious adverse reactions in nursing infants.

Q: What clinical trials or evidence led to the approval of Cataflam QS?

Official approval was based on data from specific controlled clinical trials and randomized controlled trials. These studies primarily investigated the drug's effectiveness for short-term use in acute conditions like mild-to-moderate pain and dysmenorrhea.

Q: What is the primary way the body eliminates the active ingredient in Cataflam QS?

The drug is primarily metabolized in the liver and eliminated from the body through the kidneys. The drug’s profile shows that the liver and kidneys are the primary organs involved in elimination.

Q: Is Cataflam QS the same drug as Voltaren?

Both Cataflam QS and Voltaren contain the active ingredient diclofenac, but they are different formulations. Cataflam QS is the immediate-release potassium salt for rapid pain relief, while Voltaren is a brand name often used for the diclofenac sodium salt or topical forms, which may be extended-release.

Q: What are the main differences between Cataflam QS and Diclofenac Sodium?

Cataflam QS uses the potassium salt of diclofenac for immediate release and faster absorption. Diclofenac sodium is often used in delayed or extended-release formulations.

Q: Is there a potential for physical dependence with Cataflam QS use?

No, as a Non-Steroidal Anti-Inflammatory Drug (NSAID), this medicine is not associated with the potential for physical dependence or withdrawal symptoms.

Q: What happens if a single dose of Cataflam QS is forgotten or missed?

If a dose is missed, official patient guidance recommends taking it as soon as it is remembered. If it is almost time for the next scheduled dose, the instruction is to skip the missed dose and resume the regular schedule. Extra medicine should not be taken to compensate for the missed dose.

How should Cataflam QS be stored and disposed of?

How to Store and Dispose of Cataflam QS (Diclofenac Potassium)

Cataflam QS tablets must be stored at controlled room temperature, which is between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The container should be kept tightly closed and protected from moisture and excessive heat to maintain product quality.

All medication must be stored out of the sight and reach of children and pets, as mandated by regulatory guidelines.

Disposal Requirements

Unused or expired tablets should be properly discarded and must not be flushed down a toilet or poured into a drain. Disposal should follow local regulations. Consult a pharmacist or local waste disposal service for the official instructions on disposing of unused medication.

Cataflam QS